news – page 7 – eisai china lnc.-爱游戏app官网入口

analysis evaluates efficacy of eribulin in metastatic her2-low breast cancer across three clinical studies

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today results from a post hoc analysis of three randomized, pivotal, phase 3 studies (embrace trial/study 305, study 301 and study304) evaluating the efficacy of eribulin mesylate (marketed as halaven^®) versus other chemotherapies (treatment of physician’s choice [tpc], capecitabine, and vinorelbine, respectively) in patients living with metastatic breast cancer (mbc) whose tumors have low or no her2 expression. these data were presented as a poster (presentation: #259p) at the european society for medical oncology (esmo) annual meeting (#esmo22), held virtually and in-person in paris, france from september 9-13, 2022.

the her2-low breast cancer subtype is a newly defined subset consisting of tumors that would have previously been considered her2-negative based on an immunohistochemistry (ihc) assay and an in situ hybridization (ish) assay. her2-low tumors express low amounts of the her2 protein, but not enough to be considered her2-positive. her2-low is defined as an ihc of 1 or 2 with a negative ish. of the approximate 288,000 new cases of female breast cancer expected to be diagnosed in the u.s. in 2022,¹ it is estimated that approximately 80-85% of patients would previously have been considered to have the her2-negative subtype. of those patients, about 60% would now be considered to have the her2-low subtype.²

“in this post-hoc analysis, the outcomes seen in mbc patients whose tumors are considered her2-low are consistent with the results of the three pivotal phase 3 clinical trials,” said dr. takashi owa, chief scientific officer, senior vice president, eisai co., ltd. “as the oncology community’s understanding of mbc continues to evolve, it’s important that we continue to evaluate the role of existing therapies in new contexts to contribute to the body of knowledge that is available to health care professionals.”

data from the post hoc analysis

the post hoc analysis included data from three trials — eribulin vs. tpc (, embrace trial/study 305), eribulin vs. capecitabine (, study 301), and eribulin vs. vinorelbine (, study 304) in patients with locally recurrent or mbc who had prior lines of chemotherapy treatments (≤2 for study 301; 2-5 for study 304 and embrace trial/study 305) including an anthracycline and a taxane. a total of 1,589 eligible patients were enrolled in the embrace trial/study 305, study 301 and study 304, and baseline characteristics were generally balanced between treatment arms in all studies.

median overall survival (os), median progression free survival (pfs) and objective response rate (orr) were analyzed. pfs and orr were measured per response evaluation criteria in solid tumors version (recist) (v1.0 for embrace trial/study 305 and study 301; v1.1 for study 304) by independent imaging review. orr was measured in evaluable patients (embrace trial/study 305) and in the intent-to-treat population (study 301 and study 304).

in the post hoc analysis, os, pfs, and orr among patients with her2-low or her2-negative status were generally similar to those of the eribulin treatment arms overall in each of the embrace trial/study 305, study 301 and study 304.^3,4,5 efficacy results for patients with her2-low and her2-negative status across all three studies are summarized in the table below:

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has filed a supplementary new drug application in japan for its in-house discovered antiepileptic drug (aed) fycompa^® (perampanel) seeking approval for an injection formulation as a new route of administration.

fycompa is a first-in-class aed discovered at eisai’s tsukuba research laboratories. the agent is a highly selective, noncompetitive ampa receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at ampa receptors on postsynaptic membranes. two oral formulations of fycompa are available in japan: a tablet and a fine granule formulation. due to concern about the risks associated with interruption of administration when the drug cannot be taken orally temporarily, such as during surgery, it is suggested that epilepsy patients should continue treatment other than via oral administration. the injection formulation was developed as a non-oral administration route to meet such medical needs, and its bioequivalence to the tablet formulation, as well as the confirmation of the safety and tolerability of the injection formulation when administered as an alternative therapy to the tablet, lead to this application. the addition of an injection formulation of fycompa, the only ampa receptor antagonist-based aed, to the product lineup is expected to provide a new treatment option for a broader range of patients.

it is estimated that there are approximately 1 million patients with epilepsy in japan, and although onset occurs at any age, it is most common in people aged 18 and younger, and the elderly.

eisai considers neurology, including epilepsy, a therapeutic area of focus and is in continued pursuit of our mission to provide “seizure freedom” to a greater number of patients living with epilepsy. eisai seeks to address the diverse needs of, as well as increasing the benefits provided to, patients with epilepsy and their families.

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its u.s. subsidiary eisai inc. has entered into a memorandum of understanding with c₂n diagnostics (“c₂n”) that will seek to build awareness about how blood-based assays in the diagnosis for people living with cognitive impairment, including alzheimer’s disease (ad), may help patients receive a timely diagnosis and appropriate treatment. collaborating with c₂n, eisai inc. will work to build awareness and develop real-world evidence to support the use of blood-based assays in people living with cognitive impairment in clinical practice outside of clinical trial settings in the u.s. blood-based assays could result in the development of new standards in clinical care that may enable timely and accurate diagnoses for people living with cognitive impairment.

the number of people with dementia is growing substantially; more than 55 million people worldwide are living with dementia, and this number is expected to increase to 78 million by 2030.¹ accurate diagnosis remains a barrier to early and proper care management; research reviews estimate that between 40 and 60 percent of adults with probable dementia are undiagnosed.² importantly, blood-based assays may be able to help identify which patients may benefit from therapy, and therefore may help streamline care and reduce healthcare spending. early detection, diagnosis and treatment of dementia protects individuals against risks from delayed or missed diagnosis and allows individuals, their families and their caregivers to plan for the future as the condition progresses.²

the development and adoption of blood-based assays as simple diagnostic tools, in every day clinical practice is an important step in improving care for people in remote and underserved communities where access to the traditional diagnostic tools of positron emission tomography (pet) and lumbar punctures are not a viable option.

in collaboration with various partners, eisai will engage in practical application of simple and less invasive diagnostic technologies and diagnostics for dementia, including blood tests, and will work to improve the medical environment in which people with dementia can receive appropriate treatment, thereby contributing to relieving anxieties of people living with dementia and their families around the world.

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and lifenet insurance company (headquarters: tokyo, president: ryosuke mori, “lifenet”) announced today that they have entered into a capital and business alliance agreement to collaborate in dementia and other areas, with the aim of helping reduce the burden of medical and nursing care for people living in japan’s aging society.

new insurance products and services will be developed by mutually leveraging eisai’s wealth of experience and network in drug discovery and disease awareness activities in the field of dementia, which it has built up over many years, and lifenet’s know-how and technologies cultivated in insurance products and related services. furthermore, eisai and lifenet will promote the creation of healthcare solutions utilizing various data and customer touchpoint owned by both companies, and expand the ecosystem that contributes to solving social issues.

under the terms of the agreement, eisai will obtain lifenet common stock worth 300 million yen through market transaction.

under the medium-term business plan“eway future & beyond”, which began in april 2021, eisai is expanding its main role in healthcare, that is, we should contribute not only to people in the medical domain but also to people in the daily living domain. eisai aim’s to evolve into a company that empowers them “to realize their fullest life” by creating solutions based on science and data in the fields with high unmet medical needs where eisai has the greatest strength, through an ecosystem developed in collaboration with other industries. this alliance will accelerate the building of a dementia ecosystem that contributes through prevention, treatment, and aftercare in a comprehensive manner.

lifenet has worked with other industry partners to provide products and services that meet the needs of the times. through this alliance, as stated in , lifenet will continue providing health and wellness tips beyond the framework of life insurance to create value in our policyholders’ lives, while creating a precedent for future generations as to what life insurance is (and should be) all about.

eisai and lifenet will contribute to solving social issues through the creation of an ecosystem while pursuing the possibility of collaborations with other companies and organizations that support the objectives of the two companies’ activities.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been included in the ftse4good index series for the 21^st consecutive year since its initial inclusion in 2002. the ftse4good index series is a global index series for socially responsible investment.

the ftse4good index series was developed by ftse russell to promote investment in companies that meet global environmental, social and governance (esg) standards. eisai received particularly high scores in “corporate governance”, “customer responsibility”, “labor standards” and “tax transparency”, among others. as of the end of june 2022, 1,092 companies worldwide and 224 japanese companies were included in the ftse4good developed index series.

currently, in addition to the msci esg leaders indexes, another global esg investment index, eisai is also listed in the ftse blossom japan index, the ftse blossom japan sector relative index, the msci japan esg select leaders index, the msci japan empowering women index (win) and the s&p/jpx carbon efficient index, which are esg investment indices for japanese stocks adopted by the government pension investment fund (gpif).

eisai’s corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. by strengthening its esg initiatives and increasing non-financial value, eisai is striving to sustainably enhance corporate value based on this concept.

for more information on our esg initiatives, please visit .

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

eisai co. ltd (headquarters: toyoko, ceo: haruo naito, “eisai”) announced today that the company will present research from its alzheimer’s disease (ad) pipeline, including new data for lecanemab (ban2401), an investigational anti-amyloid beta (aβ) protofibril antibody for the treatment of mild cognitive impairment (mci) due to alzheimer’s disease (ad) and mild ad (collectively known as early ad) with confirmed presence of amyloid pathology in the brain, at the (aaic) to be held in san diego, ca and virtually from july 31 to august 4, 2022. eisai will present data and research in three oral and 18 poster presentations at the meeting.

on july 5, 2022 (u.s), eisai announced that the u.s. food and drug administration (fda) accepted the biologics license application (bla) for lecanemab under the accelerated approval pathway and was granted priority review, with a prescription drug user fee act (pdufa) action date of january 6, 2023. the readout of the primary endpoint data of clarity ad will occur in the fall of 2022. the fda has agreed that the results of clarity ad when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab.

key eisai aaic presentations

· effect of genotype on aria-e incidence by lecanemab: results from a modeling simulation to evaluate the effect of apoe4 genotype on aria-e incidence from study 201 core and comparison to the observed incidence in the open-label extension among those newly treated with lecanemab. (virtual developing topics #69402)

· lecanemab subcutaneous dosing:

* results from a study in healthy subjects to evaluate the absolute bioavailability, pharmacokinetics, safety, and immunogenicity of lecanemab following a single fixed 700 mg subcutaneous dose. (poster/abstract #69438)

* modeling and simulation analysis aimed at showing the equivalence of fixed weekly subcutaneous dose of lecanemab to body weight-based 10mg/kg biweekly intravenous dose. (poster/abstract #69429)

· ethnic and racial diversity in eisai clinical trials: an evaluation of us enrollment across lecanemab (study 201 and clarity ad) and elenbecestat missionad studies in early ad to assess racial and ethnic groups and the impact of eligibility criteria in the united states. (poster/abstract # 69198)

· β-amyloid assays predict brain β-amyloid pathology: data from the eisai and sysmex collaboration reporting on the fully automated plasma aβ40 and aβ42 immunoassays and their performance for predicting brain aβ pathology defined by amyloid pet. (poster/abstract # 68727)

· comprehensive csf tau profiling from dominantly inherited alzheimer network (dian): an oral presentation that shares results from a study in patients enrolled in washington university school of medicine’s dian-observational cohort that used eisai’s anti-microtubule binding region (mtbr) antibody, e2814, to profile mtbr-tau and then assessed timing to mtbr-tau changes in csf and correlation to clinical, cognitive, and biomarker changes. (oral presentation # 65313)

“the lecanemab data eisai will present at aaic 2022 continues to build the body of knowledge about our investigational anti-amyloid beta protofibril antibody as we work toward the phase 3 confirmatory clarity ad readout this fall,” said michael irizarry, m.d., senior vice president, deputy chief clinical officer, alzheimer’s disease and brain health, eisai inc. “additional research presented will highlight eisai’s efforts to improve ethnic and racial diversity in our early alzheimer’s disease clinical trials in the united states so that study populations mirror the u.s. medicare population, as well as research from our collaboration with sysmex on potential biomarkers that may contribute to early diagnosis of alzheimer’s disease.”

aaic 2022 presentations relating to eisai’s key compounds and research

■ eisai oral presentations

this release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. there is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.

media contact:

eisai co., ltd.

public relations department

tel: 81-(0)3-3817-5120

eisai inc. (u.s.)

libby holman

1-201-753-1945

second publication on the potential value of lecanemab in patients with early alzheimer’s disease using simulation modeling

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) today announced publication of results from an early phase evaluation that aimed to estimate potential economic value of its investigational anti-amyloid-beta (aβ) protofibril antibody lecanemab in people living with early alzheimer’s disease (ad) using a validated disease simulation model, ad archimedes condition event (ad ace) model^1,2,3 from the healthcare payer and societal perspectives in the united states, in the peer-reviewed journal neurology and therapy. this is the second publication of lecanemab’s potential value. it follows the evaluation of the long-term health outcomes using simulation modeling of lecanemab published in neurology and therapy in april 2022.⁴ while the healthcare payer perspective focuses on direct care costs (e.g., outpatient and inpatient services, medications, intervention costs, nursing home and home healthcare services), the societal perspective further considers societal costs (e.g., productivity loss and informal care costs). as reported in the previous publication, it was suggested that compared to standard of care* (soc), individuals treated with lecanemab in addition to soc (lecanemab soc) may potentially experience slower disease progression to mild, moderate and severe ad from baseline by 2.51, 3.13 and 2.34 years on average, respectively. the preliminary results of this model-based simulation could possibly translate into additional quality-adjusted life years (qaly**) and reduction in the formal and informal care costs***. additionally, the ad ace model framework used in this study allowed assessment of the potential value of lecanemab in different scenarios and sensitivity analyses, including the impact of patient subsets, alternative treatment stopping rules**** and potential dosing regimens as well as major sources of uncertainty.

eisai is committed to conducting and sharing these types of clinical and socioeconomic analyses to establish trust as we work to potentially bring lecanemab to people living with early ad who have confirmed presence of amyloid pathology in the brain. to that end, eisai would like to provide a common foundation for stakeholders’ discourse regarding the potential clinical and socioeconomic value of lecanemab from the societal perspective, not to assign a price for lecanemab at this time.

this model-based simulation was conducted using the results of a phase 2b clinical trial (study 201) evaluating the efficacy and safety of lecanemab for early ad with confirmed amyloid pathology as well as published literature. it also estimated the potential economic value of lecanemab soc over a broad range of willingness-to-pay thresholds from $50,000 to $200,000 per qaly gained as recommended by the institute for clinical and economic review (icer)*****. lecanemab soc was predicted to result in a gain of 0.61 qalys and a decrease in total non-treatment costs of $8,707 per person from the healthcare payer perspective (societal perspective: 0.64 qalys gain and $11,214 decrease) compared to the soc for patients with early ad who have confirmed presence of amyloid pathology. the potential annual value-based price (vbp) of lecanemab was estimated at $9,249 to $35,605 (societal perspective: $10,400 to $38,053) based on this early economic assessment.

icer’s value framework⁵ indicates that value cannot be wholly derived from measures of clinical and cost-effectiveness, so contextual considerations and an examination of other benefits and disadvantages are also added into the framework when assessing long-term value. this may lead to using the societal perspective and higher end of the broad range of willingness-to-pay threshold in estimating the justifiable price of lecanemab, given the large societal burden of ad relative to direct healthcare costs.

many people living with ad received informal care from their family and friends totaling more than 16 billion hours of unpaid care valued at $271.6 billion in the u.s. in 2021.⁶these predicted and simulated findings suggest that early treatment with lecanemab may reduce these costs and economic burdens, and provide insights for healthcare decision-makers regarding the potential clinical and socioeconomic value of lecanemab. the phase 3 lecanemab clarity ad data will soon be available to inform the model inputs and refine the findings. in the event that lecanemab receives the u.s. food and drug administration’s (fda) approval, eisai may determine a vbp using this framework along with other considerations, such as affordability, health system sustainability, etc.

“eisai’s goal is to create therapies, such as our investigational anti-amyloid beta protofibril antibody lecanemab, that may help impact the anxieties of people living with alzheimer’s disease and their families. for alzheimer’s disease, it is important to evaluate the holistic value of therapies taking into account not only medical costs but also the immense societal costs,” said ivan cheung, senior vice president, president neurology business group and global alzheimer’s disease officer, eisai co., ltd., chairman and ceo, eisai inc. “as part of eisai’s commitment to our human health care mission, trust and transparency, we will continue to publish data and information about lecanemab and look forward to sharing the results of the lecanemab confirmatory phase 3 clarity ad clinical trial this fall.”

eisai completed lecanemab’s rolling submission of a biologics license application (bla) for the treatment of early ad to the fda under the accelerated approval pathway in may 2022. the clarity ad phase 3 clinical study for lecanemab in early ad is ongoing and completed enrollment in march 2021 with 1,795 patients. the readout of the primary endpoint data of clarity ad will occur in the fall of 2022. the fda has agreed that the results of clarity ad, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. dependent upon the results of the clarity ad clinical trial, eisai may submit for full approval of lecanemab to the fda during eisai’s fiscal year 2022, which ends in march2023. in japan, in march 2022, eisai initiated submission of application data to the pharmaceuticals and medical devices agency (pmda) under the prior assessment consultation system with the goal of obtaining early approval for lecanemab, and aims to file for the manufacturing and marketing approval based on the results of clarity ad during eisai’s fiscal year 2022. also, in europe, based on the results of the clarity ad study, eisai plans to submit a new drug application in fiscal year 2022.

this release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. there is no guarantee that such an investigational agent will successfully complete clinical development or gain health authority approval.

* standard of care (soc) for ad currently consists of lifestyle modifications and pharmacologic treatment of symptoms.

** the quality-adjusted life year (qaly) is a measure of the value of health outcomes. since health is a function of length of life (i.e., quantity) and quality of life (qol), the qaly was developed as an attempt to combine the value of these attributes into a single index number. one qaly equates to one year in perfect health. qaly scores range from 1 (full health) to 0 (dead). for example, a new intervention may increase length of life by 3 years and improve quality of life by 70% (qaly score of 2.1) compared to an existing intervention that may increase length of life by 3 years and only improve qol by 50% (qaly score of 1.5), the incremental qaly for this new intervention will be 0.6 qalys.

*** formal and informal care costs do not include lecanemab drug cost.

**** alternative treatment stopping rules were explored in scenario analyses where treatment with lecanemab was stopped after a fixed duration of 1.5, 3 and 5 years.

***** icer is a non-profit research organization in the u.s. that evaluates the evidence on the clinical and economic value of prescription drugs, medical tests, devices and health system delivery innovations.

¹kansal ar, tafazzoli a, ishak kj, krotneva s. alzheimer’s disease archimedes condition-event simulator: development and validation. alzheimers dement (ny). 2018;4:76-88. published 2018 feb 16. doi:10.1016/j.trci.2018.01.001.

² tafazzoli and kansal. disease simulation in drug development, external validation confirms benefit in decision making. the evidence forum. 2018.

³tafazzoli a, weng j, sutton k, et al. validating simulated cognition trajectories based on adni against 436 trajectories from the national alzheimer’s coordinating center (nacc) dataset. 11th edition of clinical trials on 437 alzheimer’s disease (ctad); barcelona, spain: 2018.

⁴tahami monfared aa, tafazzoli a, ye w, chavan a, zhang q. long-term health outcomes of lecanemab in patients with early alzheimer’s disease using simulation modeling. neurol ther 11, 863–880 (2022). https://link.springer.com/article/10.1007/s40120-022-00350-y.

⁵icer value framework 2020-2023. 2022.

⁶ alzheimer’s association. 2022 alzheimer’s disease facts and figures 2022 available from:

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

eisai inc. us

libby holman

201-753-1945

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that eisai has acquired a majority of the shares issued by arteryex inc. (headquarters: tokyo, ceo: li dongying, “arteryex”), a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of march 31, 2022. the two companies will work together to develop and provide phr (personal health record)-related services for patients, healthcare professionals and society at large.

eisai launched its medium-term business plan “eway future & beyond” in april 2021, where the perspective to be shifted from that of patients to the people or each consumer. with “empowering the people to realize their fullest life” as the vision, eisai delivers not only pharmaceutical products but also solutions to the people, by utilizing the latest digital technology such as ai, and aims to remove the anxiety of the people.

arteryex has excellent software development capabilities and has developed its own phr-related product services, including apps for storing and converting health-related information of patients undergoing treatment and a wide range of users into data, as well as apps for companies for employee health management.

eisai aims to strengthen and rapidly expand its digital solution business base by acquiring arteryex’s development capabilities and quality phr products through the subsidiary acquisition. in addition to reaching a new customer segment of existing products, eisai will promote developing products including new applications by utilizing arteryex’s input technology and systems used in image data. furthermore, eisai will advance the utilization of data acquired through phr-related products, as the entire eisai group, leveraging the data management know-how that eisai has practiced in its medicine creation activities and disease awareness activities.

for building the eisai universal platform (eup), through those initiatives, eisai will enhance creating a packaged solution, as well as strengthen its delivery infrastructure, for maintenance and improvement of health, prevention and disease awareness, and will expand its contribution to the people.

the current management team of arteryex will remain after the conversion to a subsidiary. the acquisition by eisai of arteryex as a subsidiary will not have a material impact on the consolidated financial results of arteryex.

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

[notes to editors]

1. about arteryex inc.

arteryex is a software planning and development company specializing in systems and application software in the medical and healthcare fields. in the era of 100 years of life, it is becoming increasingly important for people to stay healthy. on the other hand, the data needed to advance medical care is fragmented and dispersed in various fields. the company’s goal is to better understand the needs of each individual and to achieve optimal health care and medical treatment for each person with combining the latest technologies, such as blockchain and ai, to maximize the use of data that is currently underutilized.

outline of arteryex

company name:	arteryex inc.
location:	1-4-4, iwamoto-cyo, chiyoda-ku, tokyo, japan
representative:	li dongying
principal businesses:	software planning and development
capital:	32 million yen
foundation:	march, 2018
number of employees:	19

for more information about arteryex, please visit

2. about phr products owned by arteryex

■ click-karte

“click-karte” is a smartphone application for general consumers that automatically converts information, such as the items listed in the medication handbook and the results of blood tests and/or medical examinations, into data by photographing them with a smartphone and uploading to the system. after launching in november 2020, the app has had more than 20,000 downloads at this point. this may contribute to simplification of data input in apps to be developed by eisai in the future.

■ with leaf

“with leaf” is a smartphone application developed for companies to manage employee health internally with the goal of promoting employee health and improving company productivity. the app is designed not only to contribute to promoting employees’ habitual exercise with application-based activities that encourage employees to practice exercise by setting the number of steps and walking distance, but also to raise awareness of employees for their health and exercise status by recording the number of steps taken, distance walked, and calories burned on a daily basis. it also has a chat function for individuals and groups, which can be used to stimulate communication among employees.

■ sasaeru note

“sasaeru note” is a system that links a smartphone application for patients with a viewing system exclusively for healthcare professionals, enabling medical personnel to capture the health status reported by patients while in the home environment. it allows patients and their families to review records of the occurrence of adverse reactions to medications, as well as enables to prevent patients and their families from unintentionally forget to report about a patient’s daily records and health status when they share the information with healthcare professionals.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it was selected as the winner of the tokyo governor prize for corporate governance of the year^® 2021, which is an award program organized by the japan association of corporate directors (jacd; chairman: yoshihiko miyauchi). the award ceremony was held on january 31, 2022.

the awards have been established to recognize the companies which have achieved and maintained the medium to long term profitability by implementing good corporate governance, since 2015. among the eligible companies for selection of the corporate governance of the year 2021, the tokyo governor prize goes to a company which has excellent corporate governance and also practices esg activities such as environmental activities, women empowerment, initiatives for diversity and work style reforms.

commenting on the reason for selecting eisai, mr. eiichiro kodama, director general for global financial city strategy, office of the governor for policy planning, tokyo metropolitan government stated, “eisai is a pioneer in incorporating its corporate philosophy into the articles of incorporation and practicing “purpose management.” with regard to corporate governance, eisai makes the most of its status as a company with a nomination committee, etc., system to clearly separate management oversight and business execution, and places great importance to dialogue with its stakeholders including patients. in terms of esg, eisai is a signatory to the united nations global compact and actively participates in climate change-related initiatives such as “re100” and the japan climate initiative. in addition, eisai is taking on the challenge of quantifying values that do not appear on the balance sheet, such as investments in human capital, with attempting to select kpis related esg including the ratio of women in management positions, analyze its relationship with pbr (price book-value ratio), and utilize the verification results for engagement with investors. eisai is actively working to tell the story of the cause-and-effect relationship between the esg initiatives and the enhancement of corporate value, thus taking on the extremely important challenge to visualize invisible value, embody the value of esg, and disseminate them.”

eisai defines its corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides” in the articles of incorporation, and shares it with its stakeholders. eisai calls this philosophy the human health care (hhc) philosophy, in one word, and believes that practicing philosophical management based on the hhc philosophy will contribute to achieving sustainable development goals (sdgs) and further enhance its corporate value.

eisai is committed to further strengthening its corporate governance in order to realize the hhc philosophy.

10 year anniversary event of the public-private partnership “london declaration”

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its ceo haruo naito participated in the online event entitled “100% committed to end ntds” celebrating the 10th anniversary of the london declaration, an international public-private partnership to eliminate neglected tropical diseases (ntds), on january 27, 2022. ceo naito represented pharmaceutical companies and highlighted the achievements of ntds elimination activities by the industry and successes achieved by multi-sectoral partnerships. he also expressed eisai’s continued support for the elimination of ntds towards the achievement of ntd road map 2021-2030 launched by the world health organization (who) last year. the 10th anniversary event aimed to recognize a decade of progress since the london declaration, to confirm the strong commitment of stakeholders to continue the efforts for ntds, and to strengthen endorsements from stakeholders to the kigali declaration on ntds, the successor of the london declaration which will be unveiled at the commonwealth heads of government meeting (chogm) scheduled for june 2022 in kigali, the capital of the republic of rwanda.

tremendous achievements have been made through public-private partnership since the launch of the london declaration to 2020. the pharma industry has contributed to the elimination of ntds via supply of medicines which resulted in donation of 13 billion high-quality treatments. forty-three countries have eliminated at least one ntd and 600 million people no longer require interventions against ntds. despite such progress, more than 1.7 billion people remain threatened by ntds.

in the event, ceo haruo naito said “our initiatives toward ntds elimination are rooted in the pharmaceutical company’s fundamental mission to deliver medicines to those who need them to treat illness and save lives. while r&d for ntds treatments have become more active after the london declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure.”

under the london declaration, eisai has been manufacturing and supplying diethylcarbamazine (dec) tablets, one of the lymphatic ﬁlariasis (lf) treatments, free of charge to the who for the elimination of lf. to date, 2.05 billion dec tablets manufactured at eisai’s vizag plant in india have been supplied to 29 countries (as of january 2022). although lf has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. eisai is committed to providing dec tablets for free to endemic countries that need dec until lf is eliminated in these countries. in addition to the supply of dec tablets, eisai is working on various initiatives such as support for the mass drug administrations (mda), disease awareness and improvements in sanitation.

furthermore, eisai is proactively engaged in development of new treatments for ntds through partnerships with global research organizations. utilizing the funding from the global health innovative technology fund (ghit fund) and others, eisai is conducting joint development of new treatments such as a new treatment for lf in collaboration with the liverpool school of tropical medicine and the university of liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the drugs for neglected diseases initiative (dndi).

eisai commits to the kigali declaration and strengthens collaborations with global partners to tackle ntds towards the achievement of ntd road map 2021-2030.

based on human health care (hhc) philosophy, eisai seeks to contribute to the health and welfare of people in developing and emerging countries. once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. eisai considers this to be a long-term investment in creating the markets for the future. eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including ntds and facilitate initiatives to improve access to medicine such as support for mdas and disease awareness activities. through these initiatives, eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

[notes to editors]

1. about neglected tropic diseases (ntds)

neglected tropic diseases (ntds) include 20 diseases that the who identifies as tropical diseases which human race must overcome. more than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of ntds infection. the spread of ntds is mainly caused by poor hygienic conditions associated with poverty. infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. in the worst cases, ntds may also result in death. the prevalence of ntds is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.

the following 20 ntds have been designated by who for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (hansen’s disease], chagas disease, human african trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

2. about london declaration on neglected tropical diseases

on january 30, 2012, the ceos of 13 pharmaceutical companies*, the bill & melinda gates foundation, who, the u.s. agency for international development (usaid), the u.k. department for international development (dfid), the world bank, and officials from ntd-endemic countries gathered in london to pledge their support for a coordinated effort to combat 10 ntds**^. the london declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat ntds.

commemorating the london declaration, january 30 has been designated as the world ntd day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of ntds. eisai is sponsoring the light up of tokyo tower to raise disease awareness and disseminate the importance of eliminating ntds. (please click for the details of the world ntd day.)

* abbvie, astrazeneca, bayer, bristol-myers squibb, eisai, glaxonsmithkline, gilead, johnson & johnson, merck (merck kgaa: germany), merck sharp & dhome, novartis, pfizer, sanofi

** guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human african trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, chagas disease, and visceral leishmaniasis

3. about kigali declaration on neglected tropical diseases

as the successor of the london declaration on ntds launched in 2012, the kigali declaration represents a collective commitment from stakeholders to fight against ntds. with the endorsements from stakeholders being initiated at the online event entitled “100% committed to end ntds”, a campaign to commemorate the 10th year anniversary of the london declaration held on january 27, 2022, the kigali declaration will be unveiled at the commonwealth heads of government meeting (chogm) scheduled for june 2022 in kigali, the capital of the republic of rwanda. to achieve the who’s ntd roadmap 2021-2030, the kigali declaration aims to tackle ntds comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics for ntds and ensuring equitable access to these ntds related products and services.

4. about lymphatic filariasis

lymphatic filariasis (lf) is an ntd transmitted to humans via carrier mosquitoes. lf causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. as a result, patients suffer mental, social and financial losses. it is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of lf. elimination of lf is possible by stopping the spread of the infection through mdas of three types of lf treatments including dec tablets.

5. about eisai’s commitment to improving global access to medicines including lf elimination program

in line with its hhc philosophy, eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

in november 2010, eisai agreed to supply a total of 2.2 billion dec tablets to the who free of charge by 2020, as there was a global shortage of high-quality dec tablets for use in mdas. in 2012, eisai became the only japanese company to participate in the london declaration, a coordinated effort to eliminate 10 ntds and the largest public-private partnership of its kind in the field of global health. at the london declaration’s fifth anniversary event held in april 2017, eisai announced its plan to supply dec tablets continuously beyond 2020, until lf is eliminated in all endemic countries where dec tablets are needed.

eisai has supplied 2.05 billion tablets to 29 countries through the who’s elimination program (as of january 2022). furthermore, in order to support the smooth implementation of the who’s mda programs, eisai is engaging in initiatives to raise public awareness of lf in endemic countries. staff members of eisai group cooperate with the relevant representatives in endemic countries to eliminate lf as early as possible.

in addition to the above-mentioned initiatives, eisai is moving ahead with new drug development projects targeting malaria and ntds such as mycetoma and lf, based on partnerships with international non-profit organizations such as the drugs for neglected diseases initiative (dndi) and medicines for malaria venture (mmv), as well as research organizations such as liverpool school of tropical medicine, university of kentucky, and the broad institute (please refer to the table below).

furthermore, eisai co-established the global health innovative technology fund (ghit fund), japan’s first public–private partnership to advance development of new health technologies for the developing world, is a member of the world intellectual property organization (wipo) re:search consortium, an international joint enterprise for the development of treatments for ntds, malaria and tuberculosis led by wipo, is a signatory to the tuberculosis drug accelerator (tbda) partnership, and is participating in the access accelerated initiative to promote prevention and treatment of non-communicable diseases.

*¹mrc: medical research council (uk); *²dod: department of defense (us); *³mmv: medicines for malaria venture (swiss); *⁴dhodh: dihydroorotate dehydrogenase; *⁵aso: anti-sense oligo-nucleotide

for further information on eisai’s access to medicines initiatives, please visit the access to medicines page on the eisai global website:

analysis evaluates efficacy of eribulin in metastatic her2-low breast cancer across three clinical studies

second publication on the potential value of lecanemab in patients with early alzheimer’s disease using simulation modeling

10 year anniversary event of the public-private partnership “london declaration”

customer service hotline

links

more information